citalopram has been researched along with Atherosclerotic Parkinsonism in 4 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 7.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 3.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Conti, MM | 1 |
| Ostock, CY | 1 |
| Lindenbach, D | 1 |
| Goldenberg, AA | 1 |
| Kampton, E | 1 |
| Dell'isola, R | 1 |
| Katzman, AC | 1 |
| Bishop, C | 1 |
| Thwaites, JH | 1 |
| Hutchinson, C | 1 |
| Collins, C | 1 |
| Kuan, WL | 1 |
| Zhao, JW | 1 |
| Barker, RA | 1 |
| Stadtland, C | 1 |
| Erfurth, A | 1 |
| Arolt, V | 1 |
4 other studies available for citalopram and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Acti | 2014 |
Neurotoxic reaction to citalopram.
Topics: Aged; Basal Ganglia Diseases; Citalopram; Depressive Disorder; Dystonia; Female; Humans; Parkinson D | 2006 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv | 2008 |
De novo onset of Parkinson's disease after antidepressant treatment with citalopram.
Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Magnetic Resonance Ima | 2000 |